Furlan Cristina, Suarez-Diez Maria, Saccenti Edoardo
Laboratory of Systems and Synthetic Biology, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.
Cancers (Basel). 2025 Aug 8;17(16):2601. doi: 10.3390/cancers17162601.
Basal-like breast cancer (BLBC) is a highly aggressive molecular subtype characterized by the strong expression of a gene cluster found in the basal or outer epithelial layer of the adult mammary gland. Patients with BLBC typically face a poor prognosis, with a shorter disease-free period and overall survival.
In this study, we explored the proteomic profiles of BLBC patients using publicly available data from two large cohorts of breast cancer patients. By integrating cluster analysis, predictive modeling, protein differential abundance expression, and network analysis, we identified and validated the presence of two distinct subgroups, characterized by 256 upregulated and 99 downregulated proteins.
We report the upregulation of spliceosome components, especially SNRPG and its partners (BUD13, CWC15, SNRNP70, ZMAT12), indicating altered splicing activity between TNBC subgroups. Collagen proteins (COL1A1, COL1A2, COL3A1, COL11A1) were associated with tumor progression and metastasis. Proteins in the CCT complex and microtubule-associated proteins (TUBA1C, TUBB) were linked to cytoskeletal structure and chemotherapy resistance. Aminoacyl-tRNA synthetases (DARS1, IARS1, KARS1) may also play a role in TNBC development.
These findings suggest the existence of novel molecular signatures that could improve TNBC classification, prognosis, and potential therapeutic targeting.
基底样乳腺癌(BLBC)是一种侵袭性很强的分子亚型,其特征是在成年乳腺的基底或外上皮层中发现的一个基因簇有强烈表达。BLBC患者通常预后较差,无病生存期和总生存期较短。
在本研究中,我们利用来自两个大型乳腺癌患者队列的公开数据,探索了BLBC患者的蛋白质组学特征。通过整合聚类分析、预测建模、蛋白质差异丰度表达和网络分析,我们识别并验证了两个不同亚组的存在,其特征分别为256种上调蛋白和99种下调蛋白。
我们报告了剪接体成分的上调,特别是SNRPG及其伙伴(BUD13、CWC15、SNRNP70、ZMAT12),这表明三阴性乳腺癌(TNBC)亚组之间的剪接活性发生了改变。胶原蛋白(COL1A1、COL1A2、COL3A1、COL11A1)与肿瘤进展和转移相关。CCT复合物中的蛋白质和微管相关蛋白(TUBA1C、TUBB)与细胞骨架结构和化疗耐药性有关。氨酰-tRNA合成酶(DARS1、IARS1、KARS1)也可能在TNBC发展中起作用。
这些发现表明存在新的分子特征,可改善TNBC的分类、预后及潜在的治疗靶点。